Key statistics
As of last trade Tiziana Life Sciences Ltd (0RP:FRA) traded at 0.905, -30.38% below its 52-week high of 1.30, set on Aug 13, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.905 |
---|---|
High | 0.905 |
Low | 0.905 |
Bid | 0.89 |
Offer | 0.94 |
Previous close | 0.925 |
Average volume | 0.00 |
---|---|
Shares outstanding | 110.66m |
Free float | 78.88m |
P/E (TTM) | -- |
Market cap | 107.34m USD |
EPS (TTM) | -0.1726 USD |
Data delayed at least 15 minutes, as of Nov 22 2024 07:07 GMT.
More ▼
Announcements
- Tiziana Life Sciences Announces Groundbreaking ALS Trial Grant Awarded by the ALS Association
- Tiziana Life Sciences to Participate in BIO-Europe 2024 to Discuss Recent Clinical Advancements, Including Positive GLP-1 Combination Study Data
- Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $10 Million
- Tiziana Life Sciences Announces Positive Results from Ozempic and Nasal Anti-CD3 Combination Study
- Tiziana Life Sciences Announces $4 Million Grant Awarded by National Institutes of Health to Study Anti-CD3 in Alzheimer’s Disease
- Tiziana Life Sciences Appoints New Chief Executive Officer
- Tiziana Life Sciences Regains Compliance with Nasdaq Listing Minimum Bid Price Rule
- Tiziana Life Sciences Granted FDA Fast Track Designation
- Tiziana Receives $3.4 Million in Non-Dilutive Funding
- Tiziana Life Sciences to Dose First Patient with Moderate Alzheimer’s Disease with Foralumab
More ▼